BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11571533)

  • 21. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.
    Arafat W; Gómez-Navarro J; Xiang J; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 2000 Sep; 7(9):1250-6. PubMed ID: 11023197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
    Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
    Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
    J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of single chain variable fragment (ScFv) and BiscFv-alkaline phosphatase fusion protein for detection of Bacillus anthracis.
    Wang SH; Zhang JB; Zhang ZP; Zhou YF; Yang RF; Chen J; Guo YC; You F; Zhang XE
    Anal Chem; 2006 Feb; 78(4):997-1004. PubMed ID: 16478089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
    Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cell surface-displayed anti-c-myc single-chain antibody: new perspectives for the genetic improvement of cellular tumor vaccines.
    de Inés C; Cochlovius B; Schmidt S; Little M
    Cancer Gene Ther; 2000 Sep; 7(9):1257-62. PubMed ID: 11023198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for cancer using tumour-specific prodrug activation.
    Harris JD; Gutierrez AA; Hurst HC; Sikora K; Lemoine NR
    Gene Ther; 1994 May; 1(3):170-5. PubMed ID: 7584078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli.
    Choi GH; Lee DH; Min WK; Cho YJ; Kweon DH; Son DH; Park K; Seo JH
    Protein Expr Purif; 2004 May; 35(1):84-92. PubMed ID: 15039070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
    Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
    Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries.
    Rubinstein DB; Stortchevoi A; Boosalis M; Ashfaq R; Guillaume T
    Cancer Res; 2002 Sep; 62(17):4985-91. PubMed ID: 12208750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
    Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cloning and expression of single chain Fv gene against human colorectal carcinoma].
    Fang J; Song JD
    Ai Zheng; 2002 Jul; 21(7):740-4. PubMed ID: 12479098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.
    Myers KA; Ryan MG; Stern PL; Shaw DM; Embleton MJ; Kingsman SM; Carroll MW
    Cancer Gene Ther; 2002 Nov; 9(11):884-96. PubMed ID: 12386827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine.
    Zhang T; Wang CY; Zhang W; Gao YW; Yang ST; Wang TC; Zhang RZ; Qin C; Xia XZ
    Vaccine; 2010 May; 28(23):3949-55. PubMed ID: 20382243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer.
    Winthrop MD; DeNardo SJ; DeNardo GL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3088s-3094s. PubMed ID: 10541348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
    von Minckwitz G; Harder S; Hövelmann S; Jäger E; Al-Batran SE; Loibl S; Atmaca A; Cimpoiasu C; Neumann A; Abera A; Knuth A; Kaufmann M; Jäger D; Maurer AB; Wels WS
    Breast Cancer Res; 2005; 7(5):R617-26. PubMed ID: 16168106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.